57149-07-2 Naftopidil AKSci O220
 
 
Loading Please Wait...
  O220    AKSci Bulk Reagent
Naftopidil
, 98% (HPLC)
 
1-[4-(2-Methoxyphenyl)piperazinyl]-3-(1-naphthyloxy)propan-2-ol




IDENTITY
CAS Number:57149-07-2
MDL Number:MFCD00242741
MF:C24H28N2O3
MW:392.49
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:125-129°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:Water: Insoluble
Form:Free Base
Research Area:cardiovascular disease

REVIEW

 Naftopidil (Flivas) is an selective alpha1-adrenergic receptor antagonist or alpha blocker with a Ki of 58.3 nM. Naftopidil (Flivas) is an antihypertensive agent. Naftopidil (Flivas) binds specifically to alpha 1-adrenoceptors. The Ki values are 58.3 nM for naftopidi. In Japan, naftopidil is being used as a treatment for the bladder outlet obstruction in patients with benign prostatic hyperplasia.

REFERENCES
[1]Himmel, Herbert M Naftopidil, a novel antihypertensive drug Cardiovascular Drug Reviews (1994), 12(1), 32-47.
[2] Yuan JinQiu; Liu Yali; Yang ZuYao; Qin Xiwen; Yang KeHu; Mao Chen; The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews Current medical research and opinion (2013), 29(3), 279-87.
[3] Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H, Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication. Hinyokika Kiyo. 2011 Jan;57(1):7-13.
[4] Masumori, Naoya Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia Therapeutics and Clinical Risk Management (2011), 7, 227-238.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
None

Hazard Statements
None

Precautionary Statements
Notavailable


RELATED PRODUCTS
F011Naftopidil dihydrochloride
O220Naftopidil

Current as of October 1, 2022


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.


CATEGORIES

 APIs and Bioactives > Alpha Blockers


PubChem
  @PubMed